Publications

Click here for a complete list of Hyung Lae Kim, MD publications.


Selected Key Publications

Kim HL, Griend Vander DJ, Yang X, Benson DA, Dubauskas Z, Yoshida BA, Chekmareva MA, Ichikawa Y, Sokoloff MH, Zhan P, Karrison T, Lin A, Stadler WM, Ichikawa T, Rubin MA, Rinker-Schaeffer C. Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers. Cancer Research. 2001;61:2833-2837.  

Kim HL, Seligson D, Liu X, Janzen N, Bui M, Yu H, Tao S, Figlin RA, Horvath S, Belldegrun AS. Using protein expressions to predict survival in clear cell renal carcinoma. Clinical Cancer Research. 2004;10:5464-5471.

Kim HL, Seligson D, Liu X, Janzen N, Bui M, Yu H, Tao S, Figlin RA, Horvath S, Belldegrun AS. Using tumor markers to predict the survival of patients with metastatic renal cell carcainoma. J Urol. 2005;173(5):1496-1501.

Glenn ST, Jones CA, Liang P, Kaushik D, Gross KW, Kim HL. Expression profiling of archival renal tumors by quantitative PCR to validate prognostic markers. BioTechniques. 2007;43(5):639-647. 

Kim HL, Sun X, Subjeck JR, Wang XY. Evaluation of renal cell carcinoma vaccines targeting carbonic anhydrase IX using heat shock protein 110. Cancer Immunol Immunother. 2007;56(7):1097-105.

Wang Y, Wang XY, Subjeck J, Kim HL. Carbonic anhydrase IX has chaperone-like functions and is an immunoadjuvant. Molecular Cancer Therapeutics.2008;7(12):3867-3877. PMCID: 2676339

Yi H, Yu X, Gao P, Wang Y, Kim HL, Subjeck JR, Wang XY. Pattern recognition scavenger receptor SRA/CD204 down-regulates TLR4 signaling dependent CD8 T-cell activation. Blood. 2009;113(23):5819-28.

Hellenthal NJ, Underwood W, Penetrante R, Litwin A, Zhang S, Wilding G, Teh BT, Kim HL. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urology. 2010;184(3):859-64.

Glenn ST, Head KL, Teh BT, Gross, KW, Kim HL. Maximizing RNA yield from archival renal tumors and optimizing gene expression analysis. J Biomol Screen. 2010;15(1):80-5. PMCID: 2902272

Wang Y, Wang XY, Subjeck JR, Shrikant PA, Kim HL. Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines. Br J Cancer. 2011;104(4):643-52. PMCID: 3049595